TOKYO, May 14, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and the National Cancer Center Japan announced today that both parties have entered into a joint research and development (R&D) agreement concerning “Basic research on the drug discovery and development to accelerate development of anticancer drugs in […]
cancer
TOKYO, Apr 23, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., (known as MSD outside the United States and Canada) announced today an application submission in Japan for the additional indication of Eisai’s in-house discovered […]
TOKYO, Mar 12, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has received orphan drug designation for LENVIMA (generic name: lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective indication for uterine body cancer, by the Ministry of […]
TOKYO, Mar 12, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has received orphan drug designation for LENVIMA (generic name: lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective indication for uterine body cancer, by the Ministry of […]
TOKYO, Mar 8, 2021 – (JCN Newswire via SEAPRWire.com) – NEC Corporation (TSE: 6701) today announced that it has joined a landmark public-private initiative, the Norwegian Precision Cancer Medicine Implementation Consortium (CONNECT), a collaboration between 22 key public and private partners for promoting precision cancer medicine. CONNECT is one of […]